ADRIAN DE CASTRO-QUIROS: Open Payments
NPI 1144614660 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,646 in 73 payments from 11 companies in 2025. Trend: 2023 $1,572 · 2024 $1,403 · 2025 $1,646
Food & beverage: $1,646
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 17 | $363 |
| Eisai Inc. | 9 | $289 |
| ABBVIE INC. | 13 | $245 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $209 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $170 |
| Lundbeck LLC | 3 | $74 |
| Almatica Pharma LLC | 3 | $72 |
| Teva Pharmaceuticals USA, Inc. | 3 | $64 |
| Vanda Pharmaceuticals Inc. | 2 | $62 |
| Alkermes, Inc. | 3 | $53 |
Products named: Auvelity, Leqembi, VRAYLAR, CAPLYTA, TRINTELLIX, REXULTI, LOREEV XR, AUSTEDO XR.
Industry payments across FL — which companies pay providers there.
